Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
An investigational pill for obstructive sleep apnea (OSA) may work especially well for postmenopausal women. A post hoc analysis of two phase 3 trials found that AD109 — a once-daily oral tablet — reduced airway obstruction and improved oxygenation significantly more in postmenopausal women than in other groups. The catch? Side effects like dry mouth and insomnia were also more common in this group.
An investigational oral drug called AD109 (aroxybutynin/atomoxetine) showed meaningful improvements in obstructive sleep apnea (OSA) — and the benefits appeared strongest in postmenopausal women. Presented at the CHEST 2026 Annual Meeting, a post hoc analysis of two phase 3 trials (SynAIRgy and LunAIRo) pooled data from 1,306 adults with mild-to-severe OSA, splitting them into 492 postmenopausal women and 807 non-menopausal participants.
OSA prevalence triples after menopause due to hormonal shifts, yet the condition is often underdiagnosed in women because their symptoms — fatigue, insomnia, depression — can be mistaken for typical menopausal complaints. AD109 offers a potential oral alternative for patients who can't tolerate CPAP therapy.
By the Numbers:
Why it matters: A well-tolerated oral OSA treatment could be a game-changer, especially for postmenopausal women who are underserved by current options. However, the higher rates of insomnia and dry mouth in this group raise real questions about long-term adherence — and researchers caution that the findings are descriptive and need formal statistical confirmation.
